Cargando…
Adamantanes for the treatment of neurodegenerative diseases in the presence of SARS-CoV-2
Advent of the acute respiratory coronavirus SARS-CoV-2 has resulted in the search for novel antiviral agents and in the repurposing of existing agents with demonstrated efficacy against other known coronaviruses in the search for an agent with antiviral activity for use during the COVID-19 pandemic....
Autor principal: | Butterworth, Roger F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031118/ https://www.ncbi.nlm.nih.gov/pubmed/36968489 http://dx.doi.org/10.3389/fnins.2023.1128157 |
Ejemplares similares
-
Anti-SARS-CoV-2 Activity of Adamantanes In Vitro and in Animal Models of Infection
por: Lim, Sun-Young, et al.
Publicado: (2022) -
Potential for the Repurposing of Adamantane Antivirals for COVID-19
por: Butterworth, Roger F.
Publicado: (2021) -
Reply to: SARS‐CoV‐2 as a Potential Trigger of Neurodegenerative Diseases
por: Outeiro, Tiago F., et al.
Publicado: (2020) -
Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites
por: Fam, Marina Sherif, et al.
Publicado: (2023) -
SARS-CoV-2, long COVID, prion disease and neurodegeneration
por: Zhao, Yuhai, et al.
Publicado: (2022)